Southwest oncology group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy

被引:26
作者
Beer, Tomasz M. [1 ]
Goldman, Bryan [2 ]
Nichols, Craig R. [3 ]
Petrylak, Daniel P. [4 ]
Agarwal, Manoj [5 ]
Ryan, Christopher W. [1 ]
Crawford, E. David [6 ]
机构
[1] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Providence Canc Ctr, Portland, OR USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[6] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
关键词
carboplatin; cisplatin; metastasis;
D O I
10.3816/CGC.2008.n.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this study was to characterize the activity and toxicity of irinotecan in metastatic platinum-refractory urothelial carcinoma. Patients and Methods: In a prospective multi-institutional phase 11 clinical trial, we evaluated the activity and safety of irinotecan 350 mg/m(2) (300 mg/m(2) in patients with previous radiation therapy to the pelvis) intravenously given every 21 days in patients with metastatic urothelial carcinoma and evidence of progression following one previous systemic chemotherapy regimen for metastatic disease that included cisplatin or carboplatin. The primary goal of this study was to evaluate the probability of confirmed complete or partial response. Results: Forty eligible patients were registered between December 2003 and December 2006. One patient had a complete response, and I had a partial response (overall response rate, 5%; 95% CI, 1%-17%). Median progression-free survival was 2.1 months (95% CI, 1.8-2.3 months). Median overall survival was 5.4 months (95% CI, 3.4-7.1 months). Toxicity was similar to that reported previously for this schedule of irinotecan. Conclusion: The response rate seen in this study is insufficient to recommend further evaluation of irinotecan in urothelial cancer that relapsed following initial platinum-based chemotherapy. Investigation of novel agents for this patient population remains a priority.
引用
收藏
页码:36 / 39
页数:4
相关论文
共 18 条
[11]   A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum [J].
Lorusso, V ;
Pollera, CF ;
Antimi, M ;
Luporini, G ;
Gridelli, C ;
Frassineti, GL ;
Oliva, C ;
Pacini, M ;
De Lena, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) :1208-1212
[12]   Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma [J].
McCaffrey, JA ;
Hilton, S ;
Mazumdar, M ;
Sadan, S ;
Kelly, WK ;
Scher, HI ;
Bajorin, DF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1853-1857
[13]   Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium [J].
Sweeney, Christopher J. ;
Roth, Bruce J. ;
Kabbinavar, Fairooz F. ;
Vaughn, David I. ;
Arning, Michael ;
Curiel, Rafael E. ;
Obasaju, Coleman K. ;
Wang, Yanping ;
Nicol, Steven J. ;
Kaufman, Donald S. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3451-3457
[14]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[15]   Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer [J].
Vaughn, DJ ;
Broome, CM ;
Hussain, M ;
Gutheil, JC ;
Markowitz, AB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :937-940
[16]  
VONDERMAASE H, 2000, P AN M AM SOC CLIN, pA329
[17]   Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma [J].
Witte, RS ;
Elson, P ;
Bone, B ;
Knop, R ;
Richardson, RR ;
Dreicer, R ;
Loehrer, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :589-593
[18]   Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial [J].
Witte, RS ;
Manola, J ;
Burch, PA ;
Kuzel, T ;
Weinshel, EL ;
Loehrer, PJ .
INVESTIGATIONAL NEW DRUGS, 1998, 16 (02) :191-195